How to Integrate Contract Packaging into Your Pharmaceutical Supply Chain Strategy
Contract packaging organizations are the last step before medicine reaches the patient. But the most forward-thinking companies treat them as something more: a strategic node in an integrated, resilient supply chain.
The forces reshaping pharmaceutical manufacturing — personalized medicine, geopolitical instability, serialization mandates, the shift toward patient self-administration — have elevated packaging from a downstream function to a strategic capability. How a company integrates its contract packaging organization (CPO) into its broader supply chain architecture can influence its speed to market, its regulatory posture, and its ability to respond when things go wrong.
This article examines where specialized CPOs fit within the CDMO ecosystem, why digitization has become a baseline expectation rather than a differentiator, and how leading companies are building packaging partnerships that deliver genuine supply chain resilience.
Last, But Not Least
Every pharmaceutical supply chain, however complex, converges on the product reaching the patient. It is the contract packager that occupies the final position in that chain — and that bears responsibility for ensuring what arrives is accurate, traceable, compliant, and safe.
That proximity to the patient shapes how a serious CPO approaches its role.
“Packaging organizations really fit into the supply chain because they are the last step before product moves to the patient. It’s really important to include contract packaging organizations in the entire supply chain — with integration across bulk manufacturing, forecasts, and market demand. That is where the packaging organization can really make the difference.”
Pieter Cervruysse, VP Customer Success & Supply Chain, Tjoapack
A CPO that is integrated into supply chain planning from the outset — with visibility into demand forecasts, manufacturing schedules, and market-specific requirements — will perform differently from one that receives finished product and packages it in isolation. The former is a supply chain partner. The latter is a vendor.
Where Specialized Packaging Fits in the CDMO Ecosystem
The pharmaceutical outsourcing landscape has matured considerably. Most companies now operate with a portfolio of external partners: drug substance CDMOs, formulation and fill-finish specialists, clinical supply organizations, and logistics providers. It’s important to understand where a specialized CPO sits within that ecosystem and when to use one versus an integrated CDMO offering.
Integrated CDMOs increasingly offer packaging as part of a broader service bundle. For some products and some companies, that integration makes sense: it reduces the number of technology transfer steps, simplifies quality agreements, and can compress timelines for straightforward programs.
But integration carries tradeoffs. A CDMO’s packaging capability is rarely its core competency, and for products with complex packaging requirements — combination devices, patient-centric kits, serialized products destined for multiple markets — the depth of expertise at a specialist CPO will typically be superior. Specialist packagers also offer a level of flexibility in batch size, format, and turnaround that integrated operations often cannot match.
Digitization as a Baseline, Not a Bonus
The stage of the digitization journey a CPO has reached has become one of the clearest indicators of whether they are leading or lagging. Serialization, track-and-trace, data integrity, and system integration with customer enterprise resource planning (ERP) and quality platforms have moved from competitive differentiators to baseline requirements.
“Serialization is really within our digital DNA. When FMD was introduced in 2019, we were already at the forefront — we had it well planned, and from that moment, we only improved. Within pharmaceutical track and trace, we track every step in the process. Every serialized pack can be tracked throughout the whole packaging journey.”
Max van Heeswijk, IT Manager, Tjoapack
The practical implications extend beyond compliance. A CPO with mature digital infrastructure can offer customers real-time visibility into packaging operations — at the level of individual serialized units, timestamped to the second. That level of granularity has value across quality management, regulatory submissions, and supply chain planning alike.
It also requires genuine investment in the integration between software systems and operational technology on the production floor: vision systems, cameras, labeling equipment, and the data flows that connect them. This is not a one-time implementation. It requires ongoing validation, continuous improvement, and close collaboration with both customers and software suppliers. For companies evaluating CPO partners, the quality of a prospective partner’s digital infrastructure deserves scrutiny. Look for whether they are serialization-compliant, and further, how deeply digital capability is embedded in their operations and how they manage the ongoing complexity of a validated, integrated technology environment.
Building Resilience Beyond Contingency Planning
The geopolitical events of recent years have made supply chain resilience a board-level concern across the pharmaceutical industry. For packaging operations specifically, resilience requires an active, anticipatory approach to market variability and demand uncertainty.
“Pharmaceutical companies need to stay ahead regardless of the geopolitical situation, regardless of conflicts — medicines always need to arrive to patients on time.”
Diana Orozco, Team Leader Customer Success, Tjoapack
The most resilient packaging partnerships are built on several interconnected capabilities. Geographic diversification matters. The ability to shift volume between facilities, or to fulfill from a different market when one supply route is disrupted.
Speed and flexibility matter. The ability to produce small batches at short notice, to execute urgent relabeling, or to pivot quickly when market demand shifts.
Deep expertise in customs, documentation, and cross-border regulatory requirements matters. A partner that can navigate the complexity of getting a product across borders quickly and without compliance risk is valuable when timelines are compressed.
“We have a sister company in the US, so if we cannot fill the market for certain products, we can always go there to assist our customers. We have strong contacts with transport companies and can help with customs documentation — and we make sure to anticipate very urgent market needs, whether that’s relabeling or producing very small batches at the right time.”
Diana Orozco & Pieter Cervruysse, Tjoapack
Integrating CPOs into your supply chain strategy
The decision of how and when to bring a specialist CPO into your supply chain is less a capability question than a strategic one. Before evaluating what a packaging partner can do, it’s worth being clear on what role you need them to play — and how deeply you want them integrated into your planning and operations.
The starting point is integration depth. A CPO engaged purely at the execution level — receive product, package it, ship it — will always be constrained in the value it can add. The companies that get the most from their packaging partnerships are the ones that bring their CPO into supply chain planning conversations early: sharing demand forecasts, flagging market-specific regulatory changes, and building the kind of operational transparency that allows a packaging partner to anticipate rather than simply react. This requires two-way integration, not just a quality agreement and a purchase order.
The second consideration is where specialization matters for your portfolio. Not every product needs a specialist CPO. When complexity enters the picture, the depth of expertise and the operational flexibility of a specialist partner will typically outperform an integrated offering that treats packaging as a supporting function.
The third consideration is resilience architecture. The pandemic and subsequent geopolitical disruptions have prompted many pharmaceutical companies to re-examine single points of failure in their supply chains. For packaging, that means asking not just whether a partner can handle your current volume and complexity, but whether they can flex when the situation changes — and whether their network and geographic footprint give you options when a primary supply route is under pressure. A partner with redundancy built into their operating model represents a lower supply chain risk.
Finally, there is the question of partner orientation, which is harder to evaluate from a capabilities checklist but ultimately determines whether a relationship delivers strategic value or simply operational throughput. The right CPO partner engages in the scoping conversation before the RFP, asks questions about the patient journey, not just the pack format, and treats problems as shared challenges rather than contractual disputes. That orientation is observable from the first conversation if you know what to look for.
The pharmaceutical supply chain has never rewarded complacency. The companies and organizations that have invested in packaging specialization — in deep technical expertise, in digital infrastructure, in genuine supply chain integration — are better positioned for the complexity ahead than those that have treated packaging as a commodity afterthought.
The questions worth asking are not just “can they package our product?” They are: can they track it, prove it, protect it, and get it to the patient — whatever the supply chain throws at them?
This article was produced in partnership with Tjoapack, a specialist contract packaging organization for pharmaceutical and biotech companies. With facilities in Europe (Netherlands) and the US (Tennessee), Tjoapack offers end-to-end packaging solutions from clinical to commercial supply.